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Abstract
Diabetes mellitus is one of the most serious problems of the clinical medicine. This is determined by the fact that it is followed 
by multisystemic affects, as well as complications on the side of other organs and systems, among which a special place is occupied by 
gastroesophageal reflux disease. As for the combination and mutual influence of diabetes mellitus and gastroesophageal reflux disease, 
this issue has not been studied yet, the data of modern literature are not complete and quite contradictory. 
The aim of the study: to investigate the state of the factors of aggression and protection of the oesophageal mucosa in patients 
with diabetes mellitus type II with concomitant gastroesophageal reflux disease without associated pathology. 
Method. There were two groups of patients under observation. The first group included 45 patients with diabetes mellitus type 
II with concomitant gastroesophageal reflux disease (26 men and 19 women). The second group included 38 patients with gastroesoph-
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ageal reflux disease without associated pathology – 20 men and 18 women. By sex, age, body weight, Helicobacter pylori infection, 
smoking and alcohol consumption, both groups were comparable. The surveillance program included determining the compensation ra-
tio of carbohydrate metabolism and the state of the factor. The antioxidant protection factor was assessed by the level of catalase activity 
in the blood serum, as well as by the diameter of the celiac trunk and the blood flow velocity in it. Statistical processing of the obtained 
data was carried out with the aid of the program WINDOWS STATISTIKA 6.0. For all types of analysis, differences were considered 
statistically significant with p<0.05. 
Results. During the study, we found that in patients with diabetes mellitus type II with concomitant gastroesophageal reflux 
disease, as well as in patients with gastroesophageal reflux disease without associated pathology, the level of pH-metry was reduced, but 
with varying measures of confidence. At the same time, we found that patients with GERD without associated pathology had a decrease 
in the blood flow velocity in the celiac trunk. Concurrently, we ascertained that the decrease in the blood flow velocity in patients of 
both groups reduced the diameter of the celiac trunk. 
Conclusions. In patients with diabetes mellitus type II, concomitant gastroesophageal reflux disease has a subtle clinical pre-
sentation that is affected by a significant decline in mucosal sealing protection factors. In patients with GERD without associated pathol-
ogy, typical clinical manifestations, accompanied by inflammation, acid regurgitation and dyspepsia, are more vivid.
Keywords: diabetes mellitus type II, gastroesophageal reflux disease, level of pH-metry, factors of aggression and protection, 
oesophageal mucosa.
DOI: 10.21303/2504-5679.2020.001080
1. Introduction 
Diabetes mellitus (DM) remains one of the most serious problems of clinical medicine, 
which is determined by its high incidence, severity of complications, disability and heavy mor-
tality [1, 2].
Every year the mortality rate of diabetic patients steadily increases, the incidence prognosis 
is about 5–7 % per year [3, 4].
In 2011, according to the European Diabetes Association, there were 266 million people in 
the world who suffered from diabetes mellitus, in addition, 4.6 million people died of this disease 
every year.
In Ukraine, more than 1.3 million people with diabetes mellitus are registered, which makes 
about 2 % of the total population of the country. At the same time, epidemiological studies have 
shown that the true incidence is 2-3 times higher [5, 6].
Already there are more than 260 million patients with diabetes mellitus in the world, which 
is 2.8 % of the world’s population, and by 2025 their number will reach 300 million. In Russia, 
according to the World Health Organization, the number of people suffering from diabetes mellitus 
is also projected to rise from 4.6 million in 2000 to 5.3 million by 2030 [7, 8].
Such dynamics is caused by the fact that diabetes mellitus is accompanied by multisystemic 
affects, as well as early and frequent complications on the side of other organs and systems, includ-
ing upper gastrointestinal, among which a special place is occupied by gastroesophageal reflux 
disease (GERD).
These concomitant diseases largely predetermine the course of diabetes mellitus and its 
complications and affect the life expectancy of the patient.
For today, the pathology of cardiovascular and renal systems in patients with diabetes melli-
tus has been studied fairly well, which is sufficiently reflected in numerous publications. However, 
the gastroenterological aspects of diabetes mellitus are much less studied.
As for the combination and mutual influence of diabetes mellitus and gastroesophageal 
reflux disease, this issue has not been studied much so far, the data of modern literature are not 
complete and are quite contradictory.
At the same time, clinical researches devoted to the study of the state of the oesophagus in 
patients with a combination of GERD and DM are few and do not give a complete answer to many 
questions on the formation and development of this comorbid pathology. In particular, there is no 
precise data on the incidence, peculiarities of the GERD course with various types of diabetes 
mellitus depending on the duration of its course and the nature of the hypoglycemic therapy. In 
addition, there has been no profound comparative analysis of changes in the secretory (acid-pro-
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ducing) function of the gaster, the peculiarities of the state of metabolic processes with underly-
ing gastroesophageal reflux disease, depending on the type of diabetes mellitus, which affect the 
pathogenetic mechanisms of GERD formation with underlying DM [12, 13].
All these facts of a few studies devoted to the investigation of the GERD formation mech-
anisms with underlying DM have not been fully clarified, and therefore require further investiga-
tion, which conditions this study.
The aim of the study: to investigate the state of the factors of aggression and protection of 
the oesophageal mucosa in patients with diabetes mellitus type II with concomitant GERD without 
associated pathology.
2. Materials and Methods 
The study was conducted from 2016 to 2019 based on the Department of Therapy, Rheuma-
tology and Clinical Pharmacology, the Gastroenterology Department of the Kharkiv City Student 
Hospital, as well as on the basis of the Endocrinology Department of the Kharkiv Regional Clinical 
Hospital.
There were two groups of patients under observation. The first group included 45 patients 
with diabetes mellitus type II with concomitant GERD (26 men and 19 women). The mean age of 
patients was 46.4±3.1 years; the body weight was 63.2±2.8 kg.
Patients of the first group in the clinical setting had in equal measure, along with the symp-
toms characteristic of DM, moderate acid regurgitation (in 25 patients, 55.5 %), dysphagia (in 22 pa- 
tients, 48.8 %), and constantly appearing inflammation (in 23 patients, 51.1 %).
The studies were carried out in accordance with the Declaration of Helsinki; the procedures 
were approved by the local ethics committee of Kharkiv medical academy of postgraduate educa-
tion, protocol No. 5, 12.11.2019. Informed consent for the participation was obtained from all the 
patients.
As a result of fibroadastroduodenoscopy, there were revealed hyperemia, oedema of the oe-
sophageal mucosa and muscular fractures in the patients, in addition 33 patients had gastroesopha-
geal reflux, and 12 (26.7 %) patients had multiple erosions of the oesophageal mucosa.
The second group (experimental) included 38 patients suffering from GERD without con-
comitant pathology – 20 men and 18 women, whose mean age was 45.6±4.1 years, and the body 
weight was 62.7±3.1 kg.
In patients with GERD without associated pathology, in the clinical setting the main symp-
toms in most patients were inflammation (in 33 patients, 86.9 %), acid regurgitation and dysphagia 
(in 26 patients, 78.9 %). Hyperaemia, muscular fractures and mucosal oedema of the lined lower 
oesophagus, revealed as a result of fibroadastroduodenoscopy, were less evident than in the pa-
tients of the first group, and gastroduodenal reflux was present in the majority of patients (in 24 pa- 
tients, 73.6 %).
The level of infection of Helicobacter pylory in both groups was insignificant and reached 
I degree of dissemination in 67 patients (87 %) and II degree in 11 patients (13 %).
Thus, by gender, age, body weight, Helicobacter pylori infection, smoking and alcohol con-
sumption, both groups were comparable.
Patients without additional concomitant pathology were taken for the study. All patients had 
no need for insulin; there were no complications of diabetes mellitus. The arterial pressure of pa-
tients of both groups did not exceed 135/85 mm. gt; the body mass index of all patients was within 
the normal range and made to 21.3±1.9 kg/m2.
The duration of the gastroesophageal reflux disease in both groups did not exceed 
5 years, the severity of the symptoms was moderate, signs of Barrett’s oesophagus and atrophy 
of the mucous membrane of the oesophagus and gaster were not revealed in fibroadastroduo-
denoscopy.
The diagnosis of GERD was determined according to the Montreal Consensus (2006), tak-
ing into account the clinical presentation and the data of the fibroadastroduodenoscopy.
The diagnosis of DM was confirmed in accordance with the criteria proposed by the WHO 
experts, including the presence of glycaemia more than 6.1 mmol/l in the fasted state.
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The exclusionary criteria were presence of other organic diseases, including diseases of the 
digestive and endocrine systems, as well as the patient’s refusal to participate in the study.
The examination program included determining the degree of compensation of carbohy-
drate metabolism by the level of glycosylated haemoglobin HbA1c by chromatographic method; 
the state of the aggression factor – according to the level of pH-metry in the body and antrum of 
the gaster.
To assess the gastric secretion we used a 24-hour pH-metry, carried out with the help of the 
Gastroscan-24 (Russia) by the standard procedure, since this procedure allows to measure the pH 
directly in the oesophagus and gaster, as well as the intragastric pH-metry, using special biolive 
pH-probes with antimony-calomel electrodes (antral and gastric) on the apparatus of IKJ-2 (gaster 
acid indicator) (production Ukraine) by a standard procedure, since this intragastric pH-metry 
allows to measure the pH directly in the gaster in the basal period, with continuous record of pH 
changes in different parts of the gaster and oesophagus.
The antioxidant protection factor (AOP) was assessed according to the level of the serum 
catalase activity determined with the aid of the standard set of IBL reagents (production Germany), 
as well as according to the diameter of the celiac trunk and the blood flow velocity in it, since the 
protective function of the oesophageal mucosa is provided by normal regeneration of the epitheli-
um and adequate state of local blood flow [14, 15].
The local blood flow was assessed by the diameter of the celiac trunk and the blood flow ve-
locity in it with the determination of PSV – peak systolic velocity and EDV – end-diastolic velocity 
by the pulsed wave Doppler sonography with colour mapping performed on the ALOKA SSD-750 
(Japan) and ULTIMA pro-30 (production Ukraine).
15 practically healthy individuals of the same sex and age were used for the comparison.
Statistical processing of the data was carried out using the WINDOWS STATISTIKA 6.0 
program. Comparison of the indices in the groups was carried out by the method of parametric 
statistics (t – Student’s test). The interrelation between the indices in the groups was estimated 
using the Pearson correlation analysis (r is the correlation coefficient). Differences were rated with 
p<0.05 for all types of analysis of statistical significance.
3. Results
In the course of the study, we found that among patients with DM with concomitant GERD, 
as well as among patients with GERD without associated pathology, the level of pH-metry was 
reduced, although with varying degrees of reliability.
In particular, in patients with GERD without concomitant pathology, the pH-metry in the 
gaster was in the range from 0.5 to 1.0, in the antrum from 4 to 5.8, and on average its level 
(0.83±0.09 and 5.2±0.1) in comparison with the group of healthy individuals for which the average 
level of pH-metry in the antrum was equal to 1.62±0.05 and in the gaster 7.1±0.1, made statistically 
significant (p<0.001) difference.
In the group of patients with DM with concomitant GERD, the acidity indices both in the 
gaster (from 0.8 to 1.5) and in the antrum (5.8–7.0) were higher, and their average level (1.40±0.1 
and 6.05±0.1) with a lesser degree of reliability (p2<0.05) differed (p1<0.05) not only from the norm, 
but also from the group of patients with GERD without associated pathology (p3<0, 05). During 
daily pH monitoring, it was noted that the highest acidity values were recorded in morning hours 
6.00–7.00 am (Table 1).
At the same time, we found that patients with GERD without associated pathology had a 
decrease in the blood flow velocity in the celiac trunk and amounted from 8 to 12 cm/sec. On av-
erage, the blood flow velocity decreased to 10.7±1.06 cm/sec, and which, in comparison with the 
control group, whose blood flow velocity in the celiac trunk was 13.5±0.92 cm/sec, the difference 
was statistically (p<0.05) reliable.
Among the patients with DM with concomitant GERD, the blood flow velocity in the celiac 
trunk decreased even more from 8 to 5 cm/sec, and on average dropped to 6.9±0.82 cm/sec, making 
a statistically significant difference not only when compared with the norm (p <0.001), but also 
with the average blood flow velocity of patients with GERD without associated pathology (p<0.05). 
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At the same time, there were no significant changes between PSV and EDV in both treatment 
groups (Table 2).
Table 1
Average parameters (table of gastric acidity) of pH-metry in patients with DM with concomitant GERD, in 
patients with GERD without associated pathology and in healthy individuals of the control group
pH-metry indices
Patients with DM with 
concomitant GERD 
n=45
Patients with GERD 
without associated 
pathology 
n=38
Control group 
n=20 р
In gaster 1.40±0.1 0.83±0.09 1.62±0.05
p1<0.05 
p2<0.001 
p3<0.01
In antrum 6.05±0.5 5.0±0.1 7.2±0.1
p1<0.05 
p2<0.001 
p3<0.05
Note: p1 – degree of reliability of the difference between the group of patients with DM with concomitant GERD and the norm; p2 – 
between the group of patients with GERD without associated pathology and the norm; p3 – between the group of patients with DM 
with concomitant GERD and the group of patients without associated pathology
Table 2
Mean indices of the blood flow in the celiac trunk and the catalase activity in patients with DM with 
concomitant GERD and patients with GERD without associated pathology
Indices
Patients with DM with 
concomitant GERD,  
n=45
Patients with GERD 
without associated 
pathology,  
n=38
Control group, 
n=20 р
Diameter of the celiac 
trunk (cm) 0.59±0.05 0.76±0.05 0.93±0.07
p1<0.001 
p2<0.05 
p3<0.05
Blood flow velocity 
(cm/sec)
6.9±0.82 10.7±1.06 13.5±0.92
p1<0.001 
p2<0.05 
p3<0.001
Catalase (U/ml) 0.27±0.025 2.7±0.029 3.8±0.017
p1<0.001 
p2<0.05 
p3<0.001
Note: p1 – the degree of reliability of the difference between the group of patients with DM with concomitant GERD and the norm; 
p2 – between the group of patients with GERD without associated pathology and the norm; p3 – between the group of patients with 
DM with concomitant GERD and the group of patients without associated pathology
Concurrently, we ascertained that the decrease in the blood flow velocity in patients of both 
groups reduced the diameter of the celiac trunk. Moreover, in patients with GERD without associ-
ated pathology (experimental group), the diameter of the celiac trunk was determined in the range 
from 0.4 to 0.8 cm, and on average its size (0.76±0.05 cm) was statistically significantly (p<0.05) 
smaller than in healthy individuals of the control group (0.93±0.07 cm).
In most patients with DM with concomitant GERD, the diameter of the celiac trunk was 
even smaller and on average its size (0.59±0.05 cm) was smaller not only in comparison with the 
norm (p<0.001), but also in comparison with the average data of the patients with GERD without 
associated pathology.
At the same time, we found that the greater microcirculatory disorders were in correlation 
with the decrease in the level of catalase activity.
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In particular, in patients with GERD without associated pathology, the level of catalase 
activity was determined in the range from 2.12 U/ml to 3.23 U/ml, and on average its level was 
(2.7±0.029) statistically significantly (p2<0.05) below the norm (3.8±0.017). 
At the same time, in the patients with concomitant GERD, the catalase activity dropped be-
low 0.23 to 0.29 U/ml, and on average its level (0.268±0.01) was statistically significantly not only 
lower than the norm (p1<0.001), but also lower than the average indices of the group of patients with 
GERD without associated pathology.
4. Discussion
The questions of the comorbid course of diabetes mellitus type II and gastroesophageal 
reflux disease represent, on the one hand, great scientific and practical interest, and on the other 
hand, they remain open on several positions.
This way, some authors believe that there is no interrelation between diabetes mellitus and 
gastroesophageal reflux disease [16, 17], while other researchers note that diabetes mellitus type II 
and gastroesophageal reflux disease often accompany each other [18, 19], and that the prevalence 
of GERD symptoms among patients with diabetes mellitus type II is higher than in the general 
population [20].
In this regard, the obtained data show that there is a pathogenetic dependence between di-
abetes mellitus type II and gastroesophageal reflux disease, which is determined by the fact that 
diabetes mellitus has a direct effect on the reduction of regional blood flow and antioxidant activ-
ity indices, which are one of the basic factors of the oesophageal mucosa protection. At the same 
time, the pathogenetic effects of diabetes mellitus have less effect on the increase of the aggression 
mechanisms of the gastric juice.
A number of researchers concludes that gastroesophageal reflux disease can be considered 
as a regular complication of diabetes mellitus [21].
In this connection, our study shows that these statements do not always take place, as in the 
vast majority of our patients gastroesophageal reflux disease has been diagnosed before the onset 
of diabetes mellitus.
Some authors state that the degree of manifestation of GERD rises with the increase of du-
ration and severity of the diabetes mellitus [15, 19].
In the context of our studies, this position is confirmed, as a connection, although not reli-
able, was established between the duration of the course of diabetes mellitus type II, the degree of 
its severity, and the severity of clinical manifestations of gastroesophageal reflux disease.
At the same time, the suggestion that one of the pathogenetic mechanisms of primary develop-
ment of GERD against the background of diabetes mellitus may be neuropathy, since it is capable of 
causing motor dysfunction of the upper digestive tract, including disorders of the lower oesophageal 
sphincter regulation [13, 18], and needs further research. However, the interest in these processes of 
disorders of the regional blood flow, antioxidant protection processes, taking an active part in the 
regulation of motor function of the digestive tract, make it possible to talk about its legitimacy.
Thus, the changes we detected in the spectrum of the studied parameters and the presence of 
a close correlation between them undoubtedly indicate that diabetes mellitus has a direct effect on 
reducing the protective properties of the oesophageal mucosa and, to a lesser extent, on increasing 
the aggression of gastric juice, thereby creating favourable conditions for the initiation and forma-
tion of GERD with underlying diabetes mellitus.
Due to the fact that in patients with diabetes mellitus type II, which is characterized by in-
veterate course and disorders of all metabolic forms, affection of the oesophagus and accordingly 
formation of GERD with various forms of its manifestation (erosive or non-erosive) is a regular event. 
Therefore, in case of diabetes mellitus type II, even with the slightest suspicion of GERD, it is nec-
essary to perform fibrogastroduodenoscopy for its early detection and timely treatment prescription.
5. Conclusions
1. In patients with diabetes mellitus type II, concomitant gastroesophageal reflux disease 
has a mild clinical presentation due to a decrease in the secretion of the gastric mucosa and an 
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increase in acidity in it that occurs against the background of a significant decrease in mucosal 
barrier protection factors, which is indicated with a high degree of reliability by decrease in the 
catalase enzyme activity, deceleration of the blood flow velocity in the celiac trunk and narrowing 
of its diameter.
2. In patients with GERD without associated pathology, the typical clinical manifestations 
accompanied by inflammation, acid regurgitation and dyspepsia are more vivid and accompanied, 
with a greater degree of certainty, by increased gastric aggression (acidity).
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Abstract
The aim of the study was to assess the prognostic value of determining the plasma concentration of NT-proBNP and ST2 in 
the patients with decompensated HF and prior acute myocardial infarction and their combination in this category of patients.
Materials and methods. There were examined 120 patients with acute myocardial infarction and stage II A-B decompen-
sated chronic HF according to the classification proposed by Vasylenko V. Kh. and Strazhesko M.D., NYHA functional class (FC) 
III–IV. The patients with Q-QS wave MI (60 individuals) and non Q MI (60 individuals) were divided into 4 groups depending on 
the treatment methods. 
Study groups were homogenous by age, gender, disease severity, duration of the post-infarction period, clinical signs of de-
compensation, which served as a basis for inclusion of the patients in the study.
All the patients underwent the six-minute walk test in a quiet 30–50-m long hospital corridor in the morning. N-terminal 
pro-B-type brain natriuretic peptide (NT-proBNP) and ST-2 were analyzed in all patients.
Results. Promising biomarkers of HF decompensation in the post-infarction period were studied. In the patients with prior 
Q-QS MI and decompensated HF, NT-proBNP level was (950.38±3.15) pmol/l (p<0.05); in the patients with prior MI without signs 
of decompensated HF, it was (580.15±3.03) pmol/l (p˂0.05); in apparently healthy individuals, the level of NT-proBNP was found to 
be (111.20±3.47) pmol/l.
ST2 level was (14.80±1.61) ng/ml, (36.00±1.43) ng/ml and (49.22±1.40) ng/ml in the patients of Group 1, Group 2 and Group 3, 
respectively (p˂0.05).
Similar changes were found in patients with decompensated HF in postinfarction period after non Q MI. 
Conclusions. The increase in plasma concentration of sST2 is associated with the activation of both neurohumoral and fi-
brous pathways and can help in detecting the patients with decompensated HF in the post-infarction period and predicting the risk 
of its development.
Our results confirmed the results of other multiple studies reporting ST2 in combination with NT-proBNP to be valuable 
tools for prognosing the development of decompensated HF in the patients with prior MI. ST2, alongside with NT-proBNP, is a 
promising biomarker to be included in the diagnostic panel for detecting acute HF and can provide additional information on risk 
stratification for such patients during hospitalization and at the time of discharge from the hospital.
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